HF
SPRB

HRT Financial’s Spruce Biosciences SPRB Stock Holding History

HRT Financial’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-505
Closed -$15K – 3594
2024
Q4 		$15K Buy
+505
New +$18.5K ﹤0.01% 2249
2023
Q2 		– Sell
-178
Closed -$29K – 3438
2023
Q1 		$29K Buy
+178
New +$33.1K ﹤0.01% 2160

Other funds holding SPRB

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HRT Financial's SPRB Position: Q1 2025 in Review

HRT Financial sold out of Spruce Biosciences (SPRB) in Q1 2025, closing a stake of 505 shares — an estimated $15K sold.

HRT Financial first reported a position in SPRB in Q1 2023 and held it in 2 quarters. The position peaked at $29K in Q1 2023. 31 funds tracked by Wall St. Rank hold SPRB as of Q1 2025.

  • HRT Financial reported no remaining Spruce Biosciences position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 505 Spruce Biosciences shares in Q1 2025, an estimated $15K.
  • HRT Financial first reported a position in Spruce Biosciences in Q1 2023 and held it in 2 quarters.
  • HRT Financial's Spruce Biosciences position peaked at $29K in Q1 2023.
  • 31 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.